Centene Corp.

Centene Corp. (CNC) Market Cap

Centene Corp. has a market capitalization of .

No quote data available.

CEO: Sarah London

Sector: Healthcare

Industry: Medical - Healthcare Plans

IPO Date: 2001-12-13

Website: https://www.centene.com

Centene Corp. (CNC) - Company Information

Market Cap: -|Sector: Healthcare

Company Profile

Centene Corporation operates as a managed care company that provides programs and services to under-insured families, and commercial organizations in the United States. It operates through four segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment offers the temporary assistance for needy families; medicaid expansion; aged, blind, or disabled; and children's health insurance programs, as well as long-term services and supports; foster care; and medicare-medicaid plans. This segment also provides healthcare products and services. The Medicare segment offers special needs and medicare supplement, and prescription drug plans. The Commercial segment provides health insurance marketplace product for individual and commercial group. The Other segment operates clinical healthcare and pharmacies, as well as offers vision and dental, behavioral health, and centralized services. It provides services through primary and specialty care physicians, hospitals, behavioral health practitioners, and ancillary providers. The company was founded in 1984 and is headquartered in Saint Louis, Missouri.

Analyst Sentiment

62%
Buy

From 22 Active Polls

1Y Forecast: $64.64

▲ +0.0% Potential Upside

Consensus Target Metrics

Low Bound

$39

Median

$66

High Bound

$80

Average

$65

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$64.64
▲ +3.89% Upside
Low Target
$39.00
-37% Risk
Median Target
$66.00
6% Mid
High Target
$80.00
29% Max

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

Sentiment volume allocation data unavailable.

Historical valuation matrix unavailable.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 CENTENE CORP (CNC) — Investment Overview

🧩 Business Model Overview

Centene operates as a managed care organization (MCO), contracting with federal and state governments to administer healthcare benefits for covered populations—most prominently Medicaid and, to a lesser degree, Marketplace (ACA) and Medicare-related populations. The company acts as the intermediary between payers (government programs) and a broad provider network (physicians, hospitals, specialists, behavioral health providers, and pharmacies).

At the core of the model is risk-based, recurring revenue: Centene receives capitation or premium-like payments to manage the healthcare utilization of enrolled members. The economic engine is the spread between (1) the payments received under program rules—including risk adjustment mechanisms—and (2) the actual cost of medical services delivered. Centene seeks to improve outcomes and reduce avoidable utilization through care management, administrative operating discipline, provider contracting strategy, and pharmacy and care coordination capabilities.

Member “stickiness” is reinforced by program continuity and recertification cycles: when state contracts renew and members remain eligible, switching among plans is typically constrained by eligibility and administrative processes. For providers, Centene’s role in coordinating care and steering utilization creates operational dependence on Centene’s program design and quality frameworks.

💰 Revenue Streams & Monetisation Model

Revenue is primarily recurring and program-driven, sourced from government-sponsored premiums/capitation for covered lives. The monetisation model is less about one-off transactions and more about sustained contract administration and utilization management across enrollment cohorts.

  • Premium/capitation revenue (core): Capitated reimbursement tied to member eligibility and risk profile.
  • Risk adjustment and quality-based components: Funding that adjusts payments for expected morbidity and performance measures, influencing both top-line and relative profitability.
  • Ancillary and care services: Additional program support services and lines that can complement medical management (varies by geography and program requirements).

The primary margin drivers are the medical cost ratio (medical expense efficiency vs. earned premium), pharmacy-related costs, administrative expense discipline, and the accuracy/benefit of risk adjustment assumptions relative to actual utilization. Over time, Centene’s value creation depends on sustaining lower trend in medical costs while meeting quality and compliance benchmarks required to maintain or win contracts.

🧠 Competitive Advantages & Market Positioning

Centene’s competitive moat is rooted in regulatory and operational barriers plus scale-driven cost control. Unlike consumer subscription businesses, managed care competitiveness is heavily determined by licensing, contracting processes, compliance systems, and execution of clinical and administrative programs at scale.

Moat mechanics (why share is hard to take)

  • Regulatory moat (hard to replicate quickly): State and federal contracting requires demonstrated ability to manage populations, meet quality and reporting requirements, and comply with program integrity rules.
  • Switching frictions / contracting cycles: Even when eligibility is transferable, plan selection is constrained by bidding, contracting timelines, and performance history. Contract renewal and win rates depend on operational track record.
  • Cost and data operating leverage: Managed care scale enables better provider contracting terms, care management workflows, and utilization controls. Efficiency improvements can compound across geographies.
  • Integrated care delivery capability: Program design, care coordination, and pharmacy management reduce avoidable utilization and improve administrative throughput.

Competitive benchmarking

Centene’s industry focus is more concentrated in government-sponsored programs, particularly Medicaid and ACA-related coverage, compared with broader or different Medicare-centric strategies.

  • Molina Healthcare (MOH): Similar government-program orientation with Medicaid scale. The competitive battleground is contract awards/renewals and medical cost discipline.
  • Humana (HUM): Heavier emphasis on Medicare Advantage. The business mix and quality incentives differ, shifting focus from Medicaid risk dynamics toward Medicare star/quality measures.
  • UnitedHealth Group (UNH) — Optum: Broader ecosystem spanning insurance and care delivery/analytics. United’s integrated capabilities can pressure margin through provider and services integration at scale.

Centene’s differentiation is less about owning large provider systems and more about executing managed care under government program constraints with operating leverage, program integrity, and clinical management intensity tailored to Medicaid/Marketplace populations.

🚀 Multi-Year Growth Drivers

Growth over a 5–10 year horizon is driven by program expansion and utilization management economics rather than product novelty. Key structural drivers include:

  • Ongoing demand for government-sponsored coverage: Medicaid eligibility and ACA Marketplace enrollment dynamics support a persistent addressable market for managed care administration.
  • Improving administrative efficiency and medical cost management: Mature execution of care management and pharmacy strategies can convert membership growth into durable earnings growth when medical costs are contained.
  • Expanded value-based arrangements and care model optimization: Participation in contracted value-based care and performance-linked incentives can improve reimbursement outcomes and risk-adjusted profitability.
  • Geographic and program contract wins/renewals: Continued ability to win state bids and sustain performance under regulatory quality measures supports compounding revenue visibility.
  • Risk adjustment sophistication: The ability to correctly anticipate morbidity and align services to risk profiles can enhance margin stability as programs evolve.

⚠ Risk Factors to Monitor

  • Regulatory and reimbursement risk: Changes in Medicaid/ACA program rules, rate setting, risk adjustment methodologies, star/quality scoring frameworks, or eligibility processes can impact revenue adequacy.
  • Medical cost trend and utilization volatility: Higher-than-expected utilization, severity shifts, or pharmacy cost inflation can pressure margins absent offsetting rate adequacy.
  • Contract concentration and bid risk: Performance under specific state contracts and the outcomes of re-bids/renewals can affect growth and earnings durability.
  • Compliance and program integrity: Managed care is sensitive to fraud/waste/abuse controls, documentation accuracy, and oversight. Compliance failures can lead to financial and operational consequences.
  • Operational and technology execution: Large-scale claims processing, care management systems, and data security create execution and cyber risk.
  • Capital and liquidity needs: MCOs must maintain required reserves and respond to regulatory capital requirements; adverse reimbursement or higher medical loss can strain capital.

📊 Valuation & Market View

Markets typically evaluate managed care insurers through a blend of earnings power and balance-sheet/capital quality rather than purely revenue growth. Common valuation frameworks include EV/EBITDA, P/E, and P/S, but the key “drivers that move the needle” are more fundamental than multiple selection:

  • Medical cost ratio durability: Trends in medical expense efficiency and the stability of the spread vs. earned premium.
  • Administrative expense leverage: Ability to grow operating income faster than underlying cost structure through scale and process discipline.
  • Risk adjustment outcomes: The extent to which program payment mechanics align with realized morbidity.
  • Quality and contract renewal confidence: Contract win rates, quality measures, and the perceived resilience to policy changes.
  • Capital adequacy and reserve strength: Insurers are valued for the capacity to absorb utilization shocks and continue contracting.

🔍 Investment Takeaway

Centene’s long-term investment case rests on a regulatory and operational moat in government-sponsored healthcare, reinforced by contracting barriers, compliance infrastructure, and scale-driven cost control. The business model monetizes the spread between program payments (including risk adjustment/quality components) and the medical cost of delivering covered care. Over time, durability depends on maintaining medical cost discipline, sustaining contract performance under evolving program rules, and executing integrated care/pharmacy management to protect profitability through enrollment and policy cycles.


⚠ AI-generated — informational only. Validate using filings before investing.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-06-30

"CNC delivered a strong rebound in 2026 Q2. Revenue was $44.38B, and net income rose to $1.09B with EPS of $2.21. YoY, revenue grew from $48.74B (Q2’25) to $44.38B (Q2’26), a -8.95% decline, while net income improved from a loss of $-0.25B to +$1.09B (turnaround). QoQ, revenue fell from $49.94B (Q1’26) to $44.38B (Q2’26), down -11.15%, but net income increased from $1.54B to $1.09B (net income -29.16% QoQ). Profitability improved versus the prior-year quarter but contracted sequentially. Net margin improved to 2.04% in Q2’26 from -0.52% in Q2’25, but fell from 3.09% in Q1’26. Gross margin also increased YoY (25.80% vs 6.05%) but was lower QoQ (25.80% vs 21.90%). Operating income was $1.38B (2.24% margin). Cash generation remained healthy: operating cash flow was $4.36B and free cash flow was $4.18B, indicating strong cash earnings conversion for the quarter. The balance sheet shows liquidity improvement: cash and short-term investments rose to $27.06B vs $23.74B in Q1’26. Equity increased to ~$22.56B. No dividends were paid; buybacks were minimal (-$4M repurchased). Total shareholder return is pressured by price action: shares are down -38.42% over 1 year."

Revenue Growth

Neutral

Revenue was $44.38B in Q2’26, down -11.15% QoQ and -8.95% YoY (vs $49.94B in Q1’26 and $48.74B in Q2’25).

Profitability

Neutral

Net income improved sharply YoY (from -$0.25B to +$1.09B; turnaround), but contracted QoQ (from $1.54B to $1.09B, -29.16%). Net margin was +2.04% vs -0.52% YoY, but fell vs 3.09% QoQ.

Cash Flow Quality

Positive

Operating cash flow was $4.36B and free cash flow $4.18B in Q2’26. Liquidity and cash generation are improving sequentially despite lower earnings vs Q1.

Leverage & Balance Sheet

Neutral

Total assets rose to ~$83.01B from ~$81.18B QoQ. Equity increased to ~$22.56B from ~$21.43B. Net debt is negative (net cash position) at about -$8.05B.

Shareholder Returns

Neutral

Price performance is weak: 1-year change is -38.42% (no evidence of >20% momentum). Dividends were 0; buybacks were negligible (-$4M).

Analyst Sentiment & Valuation

Neutral

Current price is $38.17 vs consensus target ~$63.46, implying upside (~+66%). Target range is $39–$80, with the low end near current levels.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Centene delivered a strong Q2 2026 with adjusted EPS of $2.51 and consolidated HBR of 89.6%, while upgrading full-year earnings power materially. The biggest swing came from Marketplace: favorable final 2025 CMS risk adjustment of ~$180 million plus June Wakely acuity confirmation and moderated utilization drove full-year 2026 Marketplace pretax margin to 4.5%–5% (from 3%). Medicare also improved, with PDP pretax margin forecast lifted to >3% (from 2%), supported by specialty drug trends below original expectations and favorable PDP 2025 settlements (~$160 million in the quarter). Medicaid remained disciplined at a 93.9% Q2 HBR and guided to ~93.5% for the year, helped by better-than-expected 7/1 rates (~5% vs ~4.5%). Offsetting risk is higher Medicaid expansion attrition ahead of OB3: states tightening eligibility lifted acuity, prompting management to hold back an incremental 50 bps rate benefit for 2H modeling. Capital actions included $260 million senior note repurchases and a higher cash/deleveraging profile.

AI IconGrowth Catalysts

  • Marketplace: June Wakely report confirmed ACA acuity hypothesis; combined with $180 million favorable final 2025 CMS risk adjustment reconciliation enabled pretax margin uplift to 4.5%–5% for full-year 2026
  • Medicaid: 7/1 rates came in better than expected, lifting full-year 2026 composite rate forecast to ~5% (from ~4.5%) and supporting margin stability with disciplined HBR execution
  • Medicare PDP: improved specialty drug trends vs prior expectations; 2026 pretax margin guidance increased to >3% (from 2% guided at start of year)
  • Medicare Advantage: accelerated progress toward breakeven as year-to-date trend runs modestly favorable vs expectations; D-SNP ~40% of portfolio and performing favorably
  • Enterprise cost: adjusted SG&A discipline (Q2 6.9% vs 7.1% prior year) and enterprise optimization actions tied to digitization/AI to support margin restoration into 2027+

Business Development

  • Partnered with ESI to leverage >$60 billion in pharmacy spend and improve cost structure for state customers/members across lines of business
  • Utilized Wakely market acuity reporting (June Wakely report; earlier Wakely March demographic report) to reprice Marketplace risk
  • Engagement with state partners and state actuaries ahead of OB3 implementation (2027) including ex parte member eligibility/exemption validation and rate adjustment planning

AI IconFinancial Highlights

  • Adjusted diluted EPS $2.51 in Q2 2026 exceeded prior expectations; CEO attributed outperformance to business strength and improved marketplace risk adjustment positioning
  • Full-year 2026 adjusted diluted EPS increased to >$4.80 (from prior outlook >$3.40); includes nonrecurring/one-time earnings ≈$0.50 tied to settlements of 2025 items
  • One-time settlement details: Marketplace final 2025 risk adjustment favorable ≈$180 million in the quarter; Medicare segment ≈$160 million largely favorable PDP 2025 risk adjustment/quality settlements; ~$0.50 of total reconciling earnings mentioned
  • Consolidated HBR 89.6% for Q2 down from 93% in Q2 2025
  • Medicaid HBR 93.9% in Q2; unchanged near-term expectations, guiding full-year 2026 Medicaid HBR ~93.5% (improved vs original 93.7% expectation discussed on Q1 call)
  • Medicaid rate impact guidance lifted to ~5% full-year 2026 (from ~4.5%); underlying mid-4s fundamental trend unchanged
  • Medicare segment: Q2 HBR 89.5% inclusive of 2025 item; PDP full-year pretax margin now >3% (from 2% originally guided)
  • Marketplace: Q2 Commercial/Marketplace HBR 79.2% (vs prior year 90.6%); full-year 2026 Marketplace pretax margin now 4.5%–5% (from 3% previously guided at end of Q1 and February initial guidance)
  • Adjusted SG&A expense ratio 6.9% in Q2 vs 7.1% last year (20 bps improvement); enterprise adjusted SG&A rate for 2026 improved by 10 basis points vs prior forecast
  • Claims payable: medical claims liability 47 days in claims payable, down 1 day vs Q1 2026 due to timing of state-directed payments

AI IconCapital Funding

  • Ended Q2 with $715 million cash for general corporate use
  • Repurchased $260 million of senior notes during Q2 2026 to delever; debt-to-cap ratio 41.6% vs 46.5% at year-end
  • Medical claims liability $20.3 billion; 47 days claims payable

AI IconStrategy & Ops

  • Medicaid OB3 readiness: investing in near real-time data exchange with states for ex parte member eligibility, exemption validation, and member outreach
  • Nationwide playbook to move members toward community engagement/education/workforce opportunities; playbook already existed in 17 states coming into 2026
  • Marketplace underwriting/risk: refiled 2026 rates in summer 2025; relied on weekly market acuity reporting and Wakely data for risk adjustment positioning
  • Medicare Advantage: portfolio optimization and duals focus; simplifying footprint and targeting duals population for 2027
  • STARS: continuing quality initiatives; derisking implemented entering 2025 to address STARS risk-adjustment limitations for lower-income complex members
  • AI strategy: integrated AI into forecasting and deployed always-on fraud/waste/abuse algorithms learning from inbound claims daily; legal department agent reviews outside counsel invoices and saves 1.5 points monthly in legal bills
  • Enterprise optimization expected to drive ~($480 million) midpoint of SG&A costs in 2026 (noted as part of GAAP guidance/reconciliation table)

AI IconMarket Outlook

  • Medicaid: full-year 2026 composite rate forecast ~5% (vs ~4.5% prior); full-year Medicaid membership now expected down 8%–9% vs 12/31/25 (vs prior view down 6%)
  • Medicaid: held back incremental 50 bps benefit of rate improvement to account for higher membership attrition and associated acuity impact in 2H 2026
  • Marketplace: full-year 2026 pretax margin expected 4.5%–5%; Marketplace membership ~3.5 million at Q2 basis with additional attrition expected in 2H due to eligibility verification
  • Medicare: full-year 2026 PDP pretax margin >3%; Medicare Advantage progressing toward breakeven with risk/medical trend described as modestly favorable YTD
  • Q3 cash/timing: expects to pay out >$3 billion of Medicaid pass-through payments sitting on balance sheet at end of Q2
  • 2027 planning anchors: Medicare Advantage breakeven/better results expected in 2027 with margin improvement thereafter; STARS headwinds expected from methodology changes/cut point increases; OB3 implementation referenced for 2027

AI IconRisks & Headwinds

  • Medicaid: membership attrition increased vs expectation (expansion population) and states tightening enrollment/eligibility ahead of OB3; raised acuity and could pressure margin despite rate progress
  • Medicaid OB3 2027: policy/regulatory changes across scope and rate setting create uncertainty; requires careful rate documentation and margin recovery while avoiding coverage disruptions
  • STARS: headwinds from artificial cut point increases, STARS program methodology changes, and ongoing uncertainty around program continuity
  • Marketplace/ACA: ongoing program integrity measures and eligibility verification may drive additional attrition and require continued vigilance in pricing for risk shifts
  • Medicare: elevated specialty drug trends remain a factor; guidance improvement reflects they are lower than original expectations through 1H 2026

Q&A: Analyst Interest

  • Topic: Medicaid enrollment attrition drivers and whether OB3 risk is pulling forward acuity/membership. Management said slight incremental attrition was mostly expansion population; attributed to enrollment/eligibility tightening in certain states preparing for OB3. They held 50 bps of rate favorability to model 2H acuity impact and noted potential pull-forward from more preventive state actions.
  • Topic: Medicaid margin progression through OB3 regulatory headwinds and whether margin can expand in 2027. Management described expansion population shifting from ~20% to ~18% by year-end and possible mid-single-digit attrition over 27–29. They emphasized different impactability vs prior redeterminations, multiple eligibility data sources, and rate/risk management tools without PHE “air cover.”
  • Topic: Exchanges risk adjustment settlement delta (2025) and full-year 2026 assumptions, plus drivers of lower cost trend in Q2. Management said Q2 reflected moderation from Q1 utilization and improved risk adjustment offset confirmed by Wakely acuity. For 2025, they reconciled $481M absolute, ~-$250M rolling estimate base, ~$230M residual, plus ~$50M other deducts refinement totaling $180M better than prior guidance.

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the CNC Q2 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
© 2026 Stock Market Info — Centene Corp. (CNC) Financial Profile